Melissa Yu, MD
Neurology · Houston, TXNPI 1831196914
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,888 of the $5,679 with a category attached, or 68.5%. Eli Lilly accounts for 69.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $4,096, more than ten times the $52 reported in 2021.
Across 17 payments — averaging $334.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- E.r. Squibb & Sons, L.L.C.$983
- Lilly USA, LLC$429
- Novo Nordisk$259
- Biogen$66
- Eisai Inc.$24
Across 153 payments — averaging $10,538 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$768K
- Biogen$598K
- Novo Nordisk AS$147K
- Eli Lilly$65K
- Genentech, Inc.$23K
- E.r. Squibb & Sons, L.L.C.$10K
What the payments were for
- Consulting fees$3,88868%
- Travel & lodging$80914%
- Food & beverage$98217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $3,918 |
| E.r. Squibb & Sons, L.L.C. | 3 | $983 |
| Lilly USA, LLC | 6 | $429 |
| Novo Nordisk | 4 | $259 |
| Biogen | 1 | $66 |
| Eisai Inc. | 1 | $24 |
How this compares
$5,679 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 22 | $98,509 |
| Memantine Hcl | 868 | $28,598 |
| NamzaricMemantine Hcl/Donepezil Hcl | 28 | $27,460 |
| Galantamine ErGalantamine Hbr | 256 | $23,801 |
| Rivastigmine | 105 | $20,722 |
| Donepezil Hcl | 638 | $9,998 |
| Memantine Hcl ErMemantine Hcl | 75 | $9,915 |
| Sertraline Hcl | 179 | $1,721 |
| Quetiapine Fumarate | 74 | $1,565 |
| Escitalopram Oxalate | 100 | $1,433 |
| Mirtazapine | 44 | $1,087 |
| Levetiracetam | 34 | $838 |
| Gabapentin | 29 | $736 |
| Duloxetine Hcl | 30 | $693 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 42 | $555 |
Paid to pharmacies, not to this prescriber.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.